 | |
| Clinical data | |
|---|---|
| Other names | 11α-Hydroxyethinylestradiol 3-(bis(2-chloroethyl)carbamate) 11α,17β-diacetate; 17α-Ethynylestra-1,3,5(10)-triene-3,11α,17β-triol 11α,17β-diacetate 3-(bis(2-chloroethyl)carbamate) |
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C29H35Cl2NO6 |
| Molar mass | 564.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cytestrol acetate is asteroidalantiestrogen and acytostaticantineoplastic agent (i.e.,chemotherapeutic) which was developed for the treatment ofbreast cancer but was never marketed.[1][2][3][4]
It is an 11α-hydroxylatedderivative ofethinylestradiol in which abis(2-chloroethyl)aminenitrogen mustardmoiety has been attached as anester at the C3 position andacetate esters have been attached at the C11α and C17β positions.[1][2][3][4] Themechanism of action of cytestrol acetate in breast cancer is two-fold: (1) acting as an antiestrogen similarly tofulvestrant orICI-164384; and (2) havingcytostatic actions via the carbamate–nitrogen mustard moiety analogously toestramustine phosphate.[1][2][3][4] The drug shows potentefficacy against breast cancer superior to that oftamoxifen inin vitro models.[1][2][3]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
